1. Home
  2. IOBT vs LTRN Comparison

IOBT vs LTRN Comparison

Compare IOBT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IO Biotech Inc.

IOBT

IO Biotech Inc.

HOLD

Current Price

$0.20

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$2.40

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOBT
LTRN
Founded
2014
2013
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
31.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
IOBT
LTRN
Price
$0.20
$2.40
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$2.25
$25.00
AVG Volume (30 Days)
890.1K
46.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
26.77
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$2.45
52 Week High
$2.79
$5.74

Technical Indicators

Market Signals
Indicator
IOBT
LTRN
Relative Strength Index (RSI) 25.94 32.85
Support Level N/A N/A
Resistance Level $0.40 $3.65
Average True Range (ATR) 0.03 0.20
MACD -0.01 -0.01
Stochastic Oscillator 4.92 6.67

Price Performance

Historical Comparison
IOBT
LTRN

About IOBT IO Biotech Inc.

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Share on Social Networks: